literature

HIV mutation literature information.

Evaluating the role of etravirine in the second-line antiretroviral therapy after failing an initial non-nucleoside reverse transcriptase inhibitor-based regimen in a resource-limited setting.

PMID: 18855659 2008 Current HIV research

Abstract: We focused on etravirine-RAMs previously described: V90I, A98G, L100I, K101E/P, V106I, V179D/F, Y181C/I/V, and G190A/S.

HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy.

PMID: 19000027 2008 AIDS research and human retroviruses

Abstract: K103N (25%), V106M (20%), and G190A (17%) were found among patients failing nevirapine- or efavirenz-containing regimens.

Transmission networks of drug resistance acquired in primary/early stage HIV infection.

PMID: 19005274 2008 AIDS (London, England)

Method: Four G190A isolates from a large transmission cluster (n=27), (GenBank accession numbers EU375798-EU375801), were assessed for baseline susceptibility to nevirapine (NVP), efavirenz (EFV), etravirine (ETV) and TMC-120.

Result: K103N, V108I, G190A, associated with resistance to NNRTIs.

Result: All 27 patients harboured the G190A and A98S mutations.

Successful application of laboratory tools for the detection of HIV drug resistance in routine clinical care in Georgia.

PMID: 19124911 2008 Georgian medical news

Abstract: G190S/A was the most frequent NNRTI mutation (42.2%), followed by K103N (28.9%).

Etravirine: a second-generation NNRTI for treatment-experienced adults with resistant HIV-1 infection.

PMID: 19881888 2008 Future HIV therapy

Conclusion: Etravirine RAMs include V90I, A98G, L100I, K101E/H/P, V106I, E138A, V179D/F/T, Y181C/I/V, G190A/S and M230L.

Table: G190A

Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients.

PMID: 17306618 2007 Journal of clinical virology

Abstract: RESULTS: Direct sequencing of DNA provirus disclosed key mutations (such as G190A/S, V106A, K103N and T215F) to RT inhibitors more frequently (7 patients out 31) than in plasma RNA (2 out of 31).

Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical human immunodeficiency virus type 1 isolate with a deletion of codon 69 in the reverse transcriptase coding region.

PMID: 17314158 2007 Journal of virology

Abstract: In this work, we have measured the in vivo fitness of HIV-1 variants containing a deletion of 3 nucleotides affecting codon 69 (Delta69) of the viral RT as well as the replication capacity (RC) ex vivo of a series of recombinant HIV-1 variants carrying an RT bearing the Delta69 deletion or the T69A mutation in a multidrug-resistant (MDR) sequence background, including the Q151M complex and substitutions M184V, K103N, Y181C, and G190A.

Molecular epidemiology of HIV type 1 in treatment-naive patients in north Ethiopia.

PMID: 17451346 2007 AIDS research and human retroviruses

Abstract: Two patients (2.2%) had the G190A mutation, which confers resistance to the nonnucleoside reverse transcriptase inhibitor, nevirapine.

HIV-1 subtype B protease and reverse transcriptase amino acid covariation.

PMID: 17500586 2007 PLoS computational biology

Method: NNRTI-selected mutations included A98G, L100I, K101E/P/N/H, K103N/S, V106A/M, V108I, V179D/E, Y181C/I/V, Y188L/C/H, G190A/S/E/Q, P225H, F227L, M230L, P236L, and K238T.

NNRTI-selected mutations at codon 190 of human immunodeficiency virus type 1 reverse transcriptase decrease susceptibility to stavudine and zidovudine.

PMID: 17640745 2007 Antiviral research

Abstract: High-level resistance to nevirapine and moderate level resistance to both stavudine and zidovudine were associated with G190S/A/E substitutions.

Abstract: Recombinant HIV-1 strains carrying G190S/A/E, G190S+T215Y, T215Y and K103N mutations were constructed to evaluate susceptibility to both NNRTIs and nucleoside RT inhibitors (NRTIs).

Browser Board

Co-occurred Entities

Filtrator